证券代码：300294 证券简称：博雅生物 公告编号：2025-060 华润博雅生物制药集团股份有限公司 关于使用银行承兑汇票支付募集资金投资项目资金 并以募集资金等额置换的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司、博雅生物）于2019 年4月15日召开第六届董事会第二十三次会议、第六届监事会第二十次会议，会 议审议通过了《关于使用银行承兑汇票支付募投项目所需资金并以募集资金等额 置换的议案》，同意公司在募集资金投资项目（以下简称募投项目）实施期间， 根据实际情况使用银行承兑汇票支付募投项目中的应付工程款、设备采购款、材 料采购款等款项，并从募集资金账户划转等额资金至公司自有资金账户。具体内 容详见公司于2019年4月15日在巨潮资讯网上披露的《关于使用银行承兑汇票支 付募投项目所需资金并以募集资金等额置换的公告》。 | 加：本年度募集资金理财产品收益、利息收入减除手续费净额 | 13,315,616.97 | | --- | --- | | 二、使用配套募集资金 | 1,085,783,062.77 | ...

Core Viewpoint - The company plans to divest 80% of its stake in Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. to focus on its core blood products business and optimize resource allocation, enhancing capital return levels [1][3]. Group 1: Transaction Details - The transaction will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with an initial listing price of 213 million yuan, subject to the valuation approved by the state-owned assets supervision authority [1]. - After the completion of the share transfer, the company will hold 10.69% of Boya Xinhao, and it will no longer be included in the company's consolidated financial statements [2]. Group 2: Business Performance - In 2024, the company reported total revenue of 1.735 billion yuan, a decrease of 34.58% year-on-year, while net profit attributable to shareholders was 397 million yuan, an increase of 67.18% compared to the previous year [2]. - The company achieved a plasma collection of 630.6 tons in 2024, representing a year-on-year growth of 10.4%, with the main entity, China Resources Boya, collecting 522.04 tons, up 11.7%, exceeding the industry average growth rate [2]. Group 3: Strategic Implications - The divestiture is expected to optimize the company's business structure, focus on core development, enhance sustainable internal growth, facilitate capital flow, and activate existing production capacity, ultimately promoting high-quality development [3].

Market Overview - The Shanghai Composite Index closed at 3653.50 points, with a change of +0.51% [1] - The total trading volume of A-shares reached 1,149.623 billion yuan [1] Technical Analysis - A total of 17 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Angli (002940) with a distance of -1.91% - Chengdu Xian Dao (688222) with a distance of -1.51% - Saiseng Pharmaceutical (300485) with a distance of -1.38% [1] Individual Stock Performance - Angli (002940) saw a daily increase of 2.02% with a turnover rate of 4.48% [1] - Chengdu Xian Dao (688222) increased by 1.47% with a turnover rate of 2.10% [1] - Saiseng Pharmaceutical (300485) experienced a slight decrease of -0.14% with a turnover rate of 3.10% [1] - Other stocks with notable performance include: - Jintai (688443) up by 1.78% - Changshan Pharmaceutical (300255) up by 2.29% - Zhizheng (603991) down by -1.69% [1]

Market Overview - The Shanghai Composite Index is at 3639.18 points with a change of 0.11% [1] - The total trading volume of A-shares is 832.786 billion yuan [1] Stocks with Death Cross - 20 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks include: - Angli (002940) with a 5-day moving average of 56.59 yuan, down 1.78% from the 10-day moving average [1] - Chengdu Xian Dao (688222) with a 5-day moving average of 23.11 yuan, down 1.64% [1] - Sai Sheng Pharmaceutical (300485) with a 5-day moving average of 14.83 yuan, down 1.40% [1] Additional Stock Data - Other stocks with significant moving average changes include: - Zhi Xiang (688443) with a 5-day moving average of 33.34 yuan, down 0.85% [1] - Changshan Pharmaceutical (300255) with a 5-day moving average of 41.59 yuan, down 0.68% [1] - Zhi Zheng (603991) with a 5-day moving average of 72.69 yuan, down 0.40% [1] Performance Summary - The performance of various stocks shows a mix of slight gains and losses, with some stocks like Angli and Chengdu Xian Dao experiencing notable declines in their moving averages [1][2] - The overall market sentiment appears cautious, reflected in the trading volumes and the number of stocks showing bearish signals [1]

（文章来源：证券日报） 证券日报网讯博雅生物8月6日在互动平台回答投资者提问时表示，公司2025年7月31日含信用账户合并 名册的股东人数为29，062户。 ...

Market Overview - The Shanghai Composite Index closed at 3568.96 points, above the six-month moving average, with a change of 0.25% [1] - The total trading volume of A-shares reached 1,180.388 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 99 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Mengsheng Electronics: 5.86% - Guanghong Technology: 4.32% - Jinyang Co., Ltd.: 3.70% [1] Detailed Stock Performance - Top performers on August 4th with deviation rates: - Mengsheng Electronics (688311): Today's change of 7.40%, turnover rate of 4.63%, six-month line at 37.68 yuan, latest price at 39.89 yuan [1] - Guanghong Technology (300735): Today's change of 6.10%, turnover rate of 4.73%, six-month line at 27.36 yuan, latest price at 28.54 yuan [1] - Jinyang Co., Ltd. (301210): Today's change of 5.60%, turnover rate of 15.69%, six-month line at 42.39 yuan, latest price at 43.96 yuan [1] Additional Notable Stocks - Other stocks with positive performance and deviation rates include: - Zhenjiang Co., Ltd. (603507): 5.00% change, 12.19% turnover, six-month line at 24.79 yuan, latest price at 25.60 yuan [1] - Baiao Chemical (603360): 5.59% change, 2.66% turnover, six-month line at 20.51 yuan, latest price at 21.16 yuan [1] - Stocks with smaller deviation rates that just crossed the six-month line include: - Deep Technology (300735): 6.10% change, 4.73% turnover, six-month line at 27.36 yuan, latest price at 28.54 yuan [1] - Qiming Information (301210): 5.60% change, 15.69% turnover, six-month line at 42.39 yuan, latest price at 43.96 yuan [1]

Group 1 - The A-share biopharmaceutical sector experienced a short-term surge, with Tian Tan Biological reaching the daily limit, and Wan Ze Shares previously hitting the limit as well [1] - Other companies such as Aidi Pharmaceutical, Zhifei Biological, Boya Biological, Bohui Innovation, and Pailin Biological also saw increases in their stock prices [1] - The news is driven by the completion of China's first copy-type Tian Tan smallpox vaccine carrier HIV vaccine Phase I clinical trial by teams from the Chinese Center for Disease Control and Prevention and the AIDS Prevention Center [1]

Group 1 - The biopharmaceutical sector experienced a short-term surge, with TianTan Bio reaching the daily limit increase [1] - WanZe Co. previously hit the limit up, indicating strong market interest [1] - Other companies such as Aidi Pharmaceutical, ZhiFei Biological, BoYa Bio, BoHui Innovation, and PaiLin Bio also saw significant gains [1]

Core Viewpoint - The article discusses the results of drug production supervision inspections conducted by the Jiangxi Provincial Drug Supervision Administration from January to June 2025, highlighting compliance and non-compliance among various pharmaceutical companies [2][3][4]. Summary by Category Inspection Results - A total of 23 pharmaceutical companies were inspected during the first half of 2025, with most companies found to be compliant with the Good Manufacturing Practice (GMP) standards [2][3]. - Specific companies such as Jiangxi Ma Kang Pharmaceutical Co., Ltd. and Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. were noted for their compliance in producing various drug forms including eye drops and traditional Chinese medicine [2][3]. Compliance Details - Companies like Jiangxi Qinfeng Pharmaceutical Co., Ltd. and Jiangxi Yichuan Pharmaceutical Technology Co., Ltd. were recognized for their adherence to GMP during inspections, covering a range of products from small volume injections to tablets [3][4]. - The inspections included checks on production lines for specific drugs, ensuring that companies met the required safety and quality standards [2][3]. Non-Compliance Issues - Some companies faced issues during inspections, although the article primarily focuses on those that complied with regulations [2][3]. - The inspections aimed to ensure that all pharmaceutical products manufactured in the province meet the necessary legal and quality standards [2][3][4].

证券代码：300294 证券简称：博雅生物 公告编号：2025-054 华润博雅生物制药集团股份有限公司 关于挂牌转让江西博雅欣和制药有限公司 80%股权进展 暨交易结果的公告 本合同项下产权交易于 2025 年 6 月 19 日至 2025 年 6 月 25 日，经上海联合 产权交易所公开挂牌，挂牌期间征集到乙方一个意向受让方，按照产权交易规则 确定乙方为产权交易标的受让方，乙方同意依法受让本合同项下产权交易标的。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、交易概述 华润博雅生物制药集团股份有限公司（以下简称公司）于 2025 年 7 月 8 日 披露了《公司关于挂牌转让江西博雅欣和制药有限公司 80%股权进展的公告》（公 告编号：2025-049），公司公开挂牌转让所持江西博雅欣和制药有限公司（以下 简称博雅欣和）80%股权，确定抚州高新区财投集团有限公司为产权交易标的受 让方，确定相应成交额为人民币 15,816.55 万元。 按照国有产权交易规则，公司近日与抚州高新区财投集团有限公司正式签署 了《上海市产权交易合同》。 二、产权交易合同主要内容 甲 ...